<DOC>
	<DOCNO>NCT01905774</DOCNO>
	<brief_summary>Thalassemia Major patient develop Iron Overload due blood transfusion intestinal iron absorption . Renal function cause Iron overload study previous study show principally tubular disfunction . In previous study Iron chelator use Deferrioxamine . In last five year oral Iron chelator introduce approved FDA , Deferasirox , ( Novartis , Switzerland USA ) . The purpose study assess renal function Thalassemia Major patient treat new oral iron chelator compare result previous study .</brief_summary>
	<brief_title>Renal Function Among Thalassemia Patients Treated Oral Chelator Deferasirox</brief_title>
	<detailed_description>Patients Thalassemia Major . The laboratory test study : Urine dip stick , Urea , Creatinine , Na , K , Uric Acid , Calcium , Phosphorus serum urine , N acetyl-b-D-glucosaminidase Urine.Blood gas also take serum sample . The overall iron accumulation also calculate base amount Packed Cells Units transfuse . The total iron burden also assess measurement Transferrin saturation Serum Ferritin .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>Patients Thalassemia Major Intermedia treat Iron chelators blood transfusion without treatment iron chelators Exclusion criterion : None relevant</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Renal Function</keyword>
</DOC>